Healthcare shares are flat in pre-market trade.
QLT Inc. (QLTI, QLT.TO) says the first patient has been dosed in
the company's Phase IIa proof-of-concept trial of QLT091001 in
adult subjects with Impaired Dark Adaptation, a condition that
results in decreased ability to recover visual sensitivity in the
dark after exposure to bright lights.
MiMedx Group (
) said it plans to sell 5 million shares in a public offering and
that underwriters will have a 30-day option to buy up to 750,000
additional shares to cover any overallotments.
The developer, maker and marketer of patent protected
regenerative biomaterials and bioimplants processed from human
amniotic membrane plans to use proceeds for product development,
sales and marketing initiatives and general corporate purposes.
MDXG closed higher 1.90% on Friday.
Finally, Cyclacel Pharmaceuticals Inc. (
), a drug developer focused in the treatment of cancer, announced
new primary endpoint data from its Phase 2 trial of oral
sapacitabine capsules, the company's lead product candidate, in
older patients with myelodysplastic syndromes (MDS).
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.